azacitidine,ivosedinib
servier
['rova', 'leusm']
#asco22 #leusm strickland: agile study (aza/ivo vs aza/placebo) results recently led to approval of aza/ivo in front-line. best long-term outcomes in those with persistent clearance of idh1m clones. high response rates in those with rtk mutations in addition to idh1m. 
Assoc Professor, UCSF hematology/BMT. Translational researcher interested in leukemia, MDS, MRD, post-HCT relapse, GVHD, & immune recon. Photos: pyknosis (IG)